1. Home
  2. AGIO vs FLYW Comparison

AGIO vs FLYW Comparison

Compare AGIO & FLYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$40.38

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Flywire Corporation Voting

FLYW

Flywire Corporation Voting

HOLD

Current Price

$17.78

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
FLYW
Founded
2007
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
AGIO
FLYW
Price
$40.38
$17.78
Analyst Decision
Buy
Buy
Analyst Count
8
14
Target Price
$38.88
$16.21
AVG Volume (30 Days)
1.2M
2.6M
Earning Date
04-29-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
450.00
EPS
N/A
0.10
Revenue
$43,011,000.00
$623,025,000.00
Revenue This Year
$76.75
$19.68
Revenue Next Year
$170.73
$15.25
P/E Ratio
N/A
$176.20
Revenue Growth
N/A
26.59
52 Week Low
$22.24
$10.11
52 Week High
$46.00
$18.92

Technical Indicators

Market Signals
Indicator
AGIO
FLYW
Relative Strength Index (RSI) 65.36 59.01
Support Level $39.31 $13.15
Resistance Level $43.72 $18.05
Average True Range (ATR) 1.76 0.76
MACD 0.30 0.01
Stochastic Oscillator 60.73 69.19

Price Performance

Historical Comparison
AGIO
FLYW

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

About FLYW Flywire Corporation Voting

Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.

Share on Social Networks: